CJC-1295 with DAC vs Ipamorelin

At a glance

CJC-1295 with DAC

A tetrasubstituted GHRH(1-29) analog bearing a Drug Affinity Complex, which binds serum albumin and dramatically extends circulating half-life versus the no-DAC form.

CJC-1295 with DAC is a synthetic peptide with the molecular formula C165H269N47O46 and a molecular weight of 3647.15 g/mol, CAS registry number 863288-34-0. The vial is sealed and lot-numbered, holds lyophilised powder, and is kept at −20°C protected from light until it ships.

CJC-1295 is an analog of the first 29 residues of growth-hormone-releasing hormone. DAC stands for Drug Affinity Complex, a chemical modification that lets the molecule bind serum albumin and circulate far longer than the unmodified peptide. The DAC and non-DAC forms are distinct compounds.

The 2 papers cited below are 2 studies in humans.

Cited on the CJC-1295 with DAC page

1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683 · SummaryHealthy adults: a single dose raised growth hormone for at least six days and IGF-1 for nine to eleven days; estimated half-life 5.8–8.1 days.
2. Ionescu M & Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PubMed 17018654 · SummaryGrowth hormone remained pulsatile under CJC-1295: trough and mean levels rose while pulse frequency was unchanged.

Ipamorelin

A pentapeptide growth-hormone secretagogue noted in the literature for its selectivity — minimal cross-activity at cortisol and prolactin pathways compared to earlier GHRPs.

Ipamorelin is a 6-residue peptide with the molecular formula C38H49N9O5 and a molecular weight of 711.85 g/mol, CAS registry number 170851-70-4. The vial is sealed and lot-numbered, holds lyophilised powder, and is kept at −20°C protected from light until it ships.

Ipamorelin is a five-residue growth-hormone secretagogue originally developed by Novo Nordisk. It was never brought to market as a medicine and is available only as a research compound.

The 2 papers cited below are 1 study in humans and 1 animal study.

Cited on the Ipamorelin page

1. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822 · SummaryIn rats and pigs, ipamorelin released growth hormone without the ACTH or cortisol release seen with GHRP-6.
2. Gobburu JV et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. PubMed 10496658 · SummaryPharmacokinetic–pharmacodynamic model in human volunteers: dose-dependent growth hormone release with a short plasma half-life.

Handling the two side by side

CJC-1295 with DAC

• Lyophilised powder is stable for years at −20°C in the dark and tolerates days at ambient temperature in transit.

Ipamorelin

• Lyophilised powder is stable for years at −20°C in the dark and tolerates days at ambient temperature in transit.

Where to go next

• CJC-1295 with DAC and Ipamorelin: full specifications, stability notes, references and the certificate for the lot in stock.
• CJC-1295 with and without DAC: how the whole group compares.
• How to read a certificate of analysis and the certificates page.